Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evorpacept plus trastuzumab and chemotherapy for metastatic HER2-positive breast cancer
2025-522012-16-00Phase 2Authorised
- Sponsor
- ALX Oncology
- Start
- Mar 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of evorpacept in breast cancer, sponsored by ALX Oncology. Primary endpoint: Overall response rate. Planned start Mar 2026; status: authorised.
02
Drugs
evorpacept
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-522012-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522012-16-00.